Terapias dirigidas en combinación con hormonoterapia en cáncer de mama avanzado HER2- negativo - page 40

SOLAR-1 (BYL719C2301)
Alpelisib in combination with fulvestrant in HR+, HER2– BC0
A phase III randomized double-blind, placebo controlled study of alpelisib in combination with
fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative
advanced breast cancer which progressed on or after aromatase inhibitor treatment
http://www.clinicaltrials.govNCT02437318